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BACKGROUND:The endocannabinoid system has previously been shown to play a role in the 
permeability and inflammatory response of  the human gut.  Our study was to determine the 
effects of endogenous AEA and 2-AG on the permeability and inflammatory response of intestinal 
epithelium under normal, inflammatory and hypoxic conditions.   
 
METHODS:Human intestinal mucosa was modelled using Caco-2 cells. Human tissue was 
collected from planned colorectal resections. Accumulation of AEA and 2-AG was achieved by 
inhibiting their metabolising enzymes URB597 (FAAH inhibitor) and JZL184 (MAGL inhibitor).  
Inflammation and ischaemia were simulated with TNFα and IFNγ and oxygen deprivation.  
Permeability changes were measured by transepithelial electrical resistance (TEER).  The role of 
the CB1 receptor was explored using CB1 knock down (CB1Kd) intestinal epithelial cells. 
Endocannabinoid levels were measured using LC-MS. Cytokine secretion was measured using 
multiplex and ELISA. 
 
RESULTS: URB597 and JZL184 caused a concentration-dependent increase in permeability via 
CB1 (p<0.0001), and decreased cytokine production.  Basolateral application of JZL184 decreased 
permeability via CB1 (p<0.0001).  URB597 and JZL184 increased the enhanced (worsened) 
permeability caused by inflammation and hypoxia (p<0.0001 and <0.05).  CB1Kd cells showed 
reduced permeability response to inflammation (p<0.01) but not hypoxia.  2-AG levels were 
increased in response to inflammation and hypoxia in Caco-2 cells.  In human mucosal tissue, 
inflammation increased the secretion of GM-CSF, IL-12, IL-13 and IL-15, which was prevented 
with ex vivo treatment with URB597 and JZL184, and inhibited by a CB1 antagonist. 
 
CONCLUSION: Endogenous AEA and 2-AG production and CB1 activation play a key 
modulatory roles in normal intestinal mucosa permeability, and also in inflammatory and hypoxic 
conditions.   
 
Keywords: Gut, Endocannabinoids, Anandamide, 2-AG, Inflammation  
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Introduction 
A key function of the gastrointestinal tract is to form a barrier between the noxious exterior 
environment and sterile submucosa, whilst actively absorbing the vital nutrients necessary for 
homeostasis  (1). This selective permeability is achieved through a set of complex mechanisms 
including the secretion of a mucous barrier at the epithelial layer, production of mucosal antibodies 
by immune cells and through a continuous layer of epithelial cells bound together by specialised 
tight junctions  (2–5). Dysregulation of these mechanisms has been shown to lead to intestinal 
diseases such as Crohn’s disease, Ulcerative Colitis, Coeliac disease, and Irritable Bowel Syndrome  
(6–9). Despite increasing interest in the factors governing permeability and inflammation within the 
gut, the responsible mechanisms have not yet been fully elucidated. 
Endocannabinoids are intercellular lipid signalling molecules derived on demand from membrane 
precursors, themselves derived from arachidonic acid  (10). The two most well described ligands 
within this system are anandamide (AEA) and 2-arachidonoyl glycerol (2-AG). AEA production 
commences with the activation of N-acyltransferase, promoting the conversion of the membrane 
lipid phosphatidylethanolamine to N-acylphosphatidylethanolamine (NAPE). This in turn is 
converted by NAPE phospholipase D (NAPE-PLD) into AEA  (11). AEA is transported across into 
the intracellular compartment and catabolised by fatty acid amide hydrolase (FAAH) and N-acyl 
ethanolamine-hydrolysing acid amidase (NAAA)  (11, 12).  2-AG is produced by the hydrolysis of 
phosphatidylinositol to diacylglycerol (13). This is converted to 2-AG by the action of 
diacylglycerol lipase (DAGL). Following its biological effects, 2-AG is transported to the 
intracellular compartment and catabolised to arachidonic acid by monoacylglycerol lipase (MAGL), 
though may also be catabolised by FAAH, serine hydrolase α-β-hydrolase domain 6 (ABHD6) and 
serine hydrolase α-β-hydrolase domain (ABHD12)  (12, 14).  Both AEA and 2-AG are agonists of 
the two major cannabinoid G-coupled protein receptors CB1 and CB2, but also at other non-classical 
sites including TRPs, PPARs, and GPR55. 
AEA and 2-AG have been shown to play roles in gut motility, nausea, and nociception  (15). We 
have also shown that AEA and 2-AG, acting at CB1, increase intestinal permeability in healthy 
Caco-2 cells, and worsen the increased permeability caused by hypoxia and cytokine-induced 
inflammation  (16, 17). These findings, taken with evidence showing that patients with active colitis 
have increased colonic levels of AEA and 2-AG, and that endocannabinoid production is increased 
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during sepsis, suggested that AEA or 2-AG acting at the CB1 receptor increase permeability and 
may act to decrease inflammation  (18, 19).  Blockade of the CB1 receptor has been shown to limit 
the hypotensive and vasodilator effects of lipopolysaccharide (LPS) in rats, and to protect the rat 
liver from endotoxaemia and prolonged the survival of rats with severe acute pancreatitis  (20–22). 
However, several studies have also shown that AEA protects against gastrointestinal disease  (23–
26).  Engel et al. found that intraperitoneal administration of AEA to mice with trinitro 
benzosulphonic acid (TNBS) induced colitis reduced macro- and microscopic colitis scores, 
reduced pro-inflammatory cytokine production and also reduced immune cell infiltration, 
suggesting decreased gut permeability  (23). More recently two similar studies showed that 
inhibition of FAAH, causing accumulation of AEA, will decrease production of pro-inflammatory 
cytokines and reduce proliferation of leucocytes and lead to decreased colitis scores in experimental 
murine colitis induced by dextran sodium sulphate (DSS)  (27, 28).  However data regarding the 
effects of AEA and 2-AG in human tissue are lacking.  We hypothesised that endogenously 
produced AEA and 2-AG may act to increase permeability via CB1 as per our previous findings  
(16, 17), whilst having a separate but simultaneous anti-inflammatory effect. 
To address the hypothesis, the aim of the present study was to determine the effects of endogenously 
produced AEA and 2-AG on the permeability and inflammatory response of intestinal epithelial 
cells under normal, inflammatory and hypoxic conditions. To achieve this we caused accumulation 
of AEA and 2-AG by inhibition of their metabolising enzymes with URB597 (a FAAH inhibitor) 
and JZL184 (a MAGL inhibitor). The role of the CB1receptor was explored using CB1 knock down 
(CB1Kd) intestinal epithelial cells and CB1 and TRPV1 antagonists in explant human colonic tissue.   
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Materials and Methods 
Caco-2 cells (European Collection of Cell Culture, Wiltshire, UK; passages 62-86) were cultured 
in T75 cell culture flasks in Minimal Essential Medium Eagle supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin/streptomycin and L-glutamine at 37°C in 5% CO2 and 95% air.  In some 
experiments, the CB1 receptor was knocked down as previously described  (29). For this, wild type 
Caco-2 cells were seeded at 2x105 cells per well in a 6-well culture plate overnight before 
transfection with 29-mer shRNA corresponding specifically to the human Cnr1 receptor gene in 
retroviral HuSH pRS plasmid vector (Gene ID = 1268; OriGene product code: TR316500; Insight 
Biotechnology Limited, Middlesex, UK) for 48h, termed CB1Kd-Caco-2. Vector control cells 
(termed control-Caco2) were transfected with non-effective 29-mer scrambled shRNA cassette in 
the pRS plasmid vector. All procedures were performed based on the manufacturer’s protocol using 
TurboFectin 8.0 transfection reagent (OriGene product code: TF81001; Insight Biotechnology 
Limited, Middlesex, UK). After 48h, cells were transferred to 96-well plates and maintained in 
complete medium with puromycin (0.06µL/mL) for selection. Within two weeks, 3 to 4 clonal 
populations of cells were selected, passaged and cultured for experiments with continued selection 
pressure. Transfection efficiency was checked by immunoblotting for CB1 receptor expression (see 
method below) using (CB1 receptor antibody (1:1000; Cambridge Bioscience # 10006590) (Koay 
et al, 2014). Two clones were further assessed for CB1 receptor knockdown by the [35S] GTPγS 
binding assay using the synthetic CB1 receptor agonist, arachidonyl-2'-chloroethylamide (ACEA) 
as per Shore et al. 2014  (30). One clone was taken forward for further experiments. 
For permeability studies, cells were seeded at 20,000 cells on 6.4mm diameter, 0.4µm pore size 
polyethylene terephthalate inserts (BD Biosciences, Bedford, UK) and grown for 14-18 days. 
Transepithelial electrical resistance (TEER) was measured using a voltohmmeter (EVOM2) (World 
Precision Instruments, Sarasota FL, USA) as an indicator of cellular permeability. Caco-2 cell 
monolayers with TEER value greater than 1000 Ω.cm2 were used. Caco-2 cell monolayers were 
washed twice in HBSS (+ N-2-hydroxyethylpintestinal permeabilityerazine-N'-2-ethanesulfonic 
acid or HEPES and P/S) and baseline TEER measured. 
To establish the effect of endocannabinoid degradation inhibition on Caco-2 permeability, URB597 
(FAAH inhibitor, IC50 low nM), JZL184 (MAGL inhibitor, IC50 low nM) (1nM-10 µM) or DMSO 
(vehicle 0.01%) were applied to the Caco-2 monolayer apical or basolateral membranes. TEER 
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measured every 30 minutes for the first 2 hours and at 8, 24, 36 and 48 hours. To identify the target 
sites of action, the receptor antagonists AM251 (100nM), AM630 (100nM), GW9662 (100nM), 
GW6471 (500nM), capsazepine (500nM), SB 366791 (100nM) and O-1918 (500nM) were co-
applied with URB597 or JZL184. The effects of 10 µM URB597 and JZL184 were also tested in 
CB1Kd Caco-2 cells. 
To investigate the effects of AEA and 2-AG basolaterally on Caco-2 cell permeability, cell 
monolayers were washed twice in HBSS and baseline TEER in each insert was measured. 
Endocannabinoids AEA and 2-AG (10µM) or vehicle (0.1% ethanol) were applied to the basolateral 
compartment of inserts and TEER was measured every 30 minutes for 2 hours and after 8, 24, 36 
and 48 hours. 
Inflammatory model 
Caco-2 cell monolayers were grown on transwell inserts. 10 ng.ml-1 interferon-gamma (IFNγ) was 
added to the basolateral compartment and after 8 hours, 10 ng.ml-1 of tumour necrosis factor-alpha 
(TNF) was added to the media for another 16 hours as previously described  (17). URB597, 
JZL184 or vehicle (DMSO 0.01%) were applied to either the apical or basolateral membranes as 
indicated. In some experiments, this protocol was carried out in the CB1Kd cells. 
Ischaemia/reperfusion model 
Caco-2 cell monolayers were grown on transwell inserts. Hypoxic conditions were simulated using 
a GasPak™ EZ Anaerobe Pouch System (BD Biosciences, Bedford, UK) for 4 hours after which 
time the cells returned to normoxia. URB597 10µM, JZL184 10µM or vehicle were applied to the 
Caco-2 membranes.  In some experiments, this protocol was carried out in the CB1Kd cells and for 
more prolonged periods of hypoxia (6 and 8 h). 
Measurement of cytokine production 
To quantify the effect of AEA, 2-AG, URB597 and JZL184 on the inflammatory response in caco-
2 cells we measured the media concentrations of two key cytokines involved in the cell stress 
response, interleukin 8 (IL-8) and IL-6, after 24 hours of incubation. Concentrations were measured 
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using ELISA according to manufacturer’s instructions (IL-8 and IL-6, both DUOSET ELISA kits 
R&D Systems Minneapolis, US).  
Measurement of endocannabinoid levels  
A quantitative LC-MS/MS method was used for analysis of AEA and 2-AG levels in cell samples, 
based on a previously reported procedure  (31).  For these experiments, Caco-2 cells were grown in 
T75 flasks and subjected to the inflammatory or ischaemia/reperfusion protocols. Cell lysates and 
medium were stored at -80°C before analysis. Internal standard (0.42 nmol AEA-d8) was added to 
a 0.4 ml aliquot of each sample followed by solvent extraction (ethyl acetate: hexane; 9:1 v/v), 
centrifugation and evaporation. Prior to analysis, each sample extract was reconstituted in 
acetonitrile. An Applied Biosystems MDS SCIEX 4000 Q-Trap hybrid triple-quadrupole–linear ion 
trap mass spectrometer (Applied Biosystems, Foster City, CA, USA) operated in positive 
electrospray ionisation mode was used in conjunction with a Shimadzu series 10AD VP LC system 
(Shimadzu, Columbia, MD, USA) using an ACE 3 C8, 100 x 2.1 mm, 3 µm particle size column 
(Advanced Chromatography Technologies Ltd., Aberdeen, UK). Quantification was performed by 
measuring specific AEA and 2-AG precursor and product ions together with a calibrated internal 
standard method. 
Human Tissue Experimentation 
Experiments on ex vivo human colonic tissue were performed by obtaining healthy colonic tissue 
from patients undergoing elective bowel resection for bowel cancer at Royal Derby Teaching 
Hospital NHS Trust, Derbyshire (n=7).  After gaining informed consent, samples of normal colon 
at least 10cm proximal to any bowel tumour were obtained immediately after resection within the 
operating theatre.  Sections of tissue 2cm x 2cm were removed from the operative sample and 
transferred on ice to the laboratory within ten minutes, in pre-chilled Eagle’s Minimum Essential 
Medium supplemented with 1% FBS 1% penicillin/streptomycin and 1% non-essential amino acids 
mixture (Sigma-Aldrich).  Once in the laboratory, samples were pinned on Stylgard plates (Living 
Systems Instrumentation, VT, US) and the mucosa with submucosa was dissected free from the 
underlying muscularis layer.  Mucosal samples were then further dissected into approximately 20 
2mm x 2mm sections and placed in individual wells of 24-well polystyrene plates (Corning 
Incorporated, USA), each containing 1ml of media, treatments with inflammation as described 
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above (IFNγ and TNFα over 24 hours), in the absence or presence of URB597 and JZL184 or 
vehicle as appropriate in duplicate (DMSO 0.01%), and in the presence of antagonists of CB1 
(AM251) and TRPV1 (SB366791). Samples were incubated for 24 hours at 37°C in 5% CO2 and 
95% humidity.  At the end of the 24 hour experimental period media was collected and stored at -
80 °C until analysis.   
Levels of the cytokine Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), IL-12, IL-
13 and IL-15, IL-1β, IL-10, MCP-1 and MIP1α were measured from undiluted media using a 
Multiplex human cytokine assay according to the manufacturer’s instructions (Merck Millipore 
Catalogue No. CYTOMAG-60K) using a Magpix plate reader (MAGPX 11326002, Luminex, 
Texas US).   
Chemicals  
AEA, 2-AG, AM251, AM630, GW9662, GW6471, SB366791 and capsazepine were purchased 
from Tocris Bioscience (Bristol, UK). JZL184 and URB597 were purchased from Sigma-Aldrich 
(Poole, UK). IFNγ and TNFα were purchased from Invitrogen (Paisley, UK). 
Statistical analysis 
TEER values are stated as the mean ± standard error (SEM). Data recorded at each time point and 
for ELISA and mass spectrometry determinations of molecular concentrations were compared using 
one-way or two-way ANOVA as indicated. The overall effect over time of each drug was measured 
using area under the curve (AUC) values. Statistical significance between manipulations and 
controls were determined by Dunnett’s post-hoc test. Significance was set at the 5% level. 
Differences between experimental groups in human tissue experiments were compared using 
repeated measures-ANOVA, using post hoc Freidman testing where appropriate.  All statistical 
analysis was performed using GraphPad Prism 7.01 (GraphPad Software Inc, La Jolla, USA). 
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Results  
The effect of FAAH and MAGL inhibition on TEER 
To determine whether inhibiting the breakdown of AEA and 2-AG had an effect on TEER, URB597 
and JZL184 were applied to the apical and basolateral compartments of Caco-2 monolayers. When 
applied to the apical membrane, URB597 (FAAH inhibitor) decreased Caco-2 monolayer resistance 
in a concentration-dependent manner, which was significantly different from vehicle at 1, 3 and 10 
µM concentrations (Figure 1A). AUC analysis of the 48hr time course showed the effect of URB597 
at the apical membrane was only inhibited by the CB1 receptor antagonist AM251 (Figure 1B). At 
the basolateral membrane, inhibition of FAAH activity with URB597 also caused a fall in TEER in 
a concentration-dependent fashion, significantly different from vehicle at 1, 3 and 10µM 
concentration after 30 minutes of incubation and 300nM after 2hr of incubation (Figure 1C), and 
this effect was inhibited by CB1 antagonist AM251, and the TRPV1 receptor antagonist capsazepine 
(Figure 1D).  
Apical application of the MAGL inhibitor JZL184 caused a decrease in TEER in a concentration-
dependent manner, which was significantly different to vehicle at 300nM, 1µM, 3µM and 10 µM 
concentrations (Figure 2A). This effect was only inhibited by the CB1 antagonist AM251 (Figure 
2B). In contrast, application of JZL184 to the basolateral membrane increased TEER in a 
concentration-dependent manner after 2 hours (Figure 2C), again inhibited by AM251 (Figure 2D).  
Effects of basolateral application of AEA and 2-AG on TEER 
We have previously reported that apical application of AEA and 2-AG to Caco-2 monolayers 
decrease TEER but basolateral application was not examined previously  (16). Based on the findings 
that basolateral application of JZL194 increased TEER, we examined the effects of basolateral 
application of AEA or 2-AG on TEER and found that 2-AG (10µM), but not AEA, increased TEER 
when applied to the basolateral membrane which was significantly different from vehicle after 2 
hours (Figure 2E). 
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Effects of FAAH and MAGL inhibition on hyper-permeability induced by cytokines or 
hypoxia 
Since increasing cellular endocannabinoid levels with either URB597 or JZL184 increased Caco-2 
permeability, we examined the effects of these compounds in times of increased permeability 
associated with inflammation or hypoxia. As expected, application of inflammatory cytokines to 
Caco-2 cells decreased TEER (Figure 3A). Application of URB597 (10 µM) or JZL184 (10 µM) at 
the apical membrane caused a further decrease in TEER beyond the effect of cytokines alone (Figure 
3A). 4h hypoxia also caused a fall in TEER of Caco-2 monolayers with recovery occurring over 
68h (Figure 3B). Application of URB597 (10µM) or JZL184 (10µM) at the apical membrane 
prevented recovery of TEER over the experimental period compared to control. The recovery in 
TEER was reduced in the presence of both URB597 and JZL184 (p<0.05 for both inhibitors at 72 
hours).  
Effects of FAAH and MAGL inhibition on CB1Kd Caco-2 TEER 
To confirm the pharmacological data suggesting that the effects of FAAH and MAGL inhibition 
on permeability were CB1-mediated, we examined these compounds in CB1Kd Caco-2 cells.  No 
effects of URB597 or JZL184 (10 µM) were found when applied to the apical or basolateral 
membranes of CB1Kd Caco-2 cells (Figure 4A).  
Effects of cytokine and hypoxia on wild type and CB1kd Caco-2 cells  
Because endogenous production of AEA and 2-AG appeared to govern paracellular permeability 
through CB1 (Figure 1B, 2B), we sought to find the effect of reducing the CB1 receptor expression 
on Caco-2 permeability under inflammatory and hypoxic conditions. Basolateral application of 
cytokines to both CB1Kd and control cells caused a decrease in TEER (Figure 4B). However, the 
fall in TEER in CB1Kd cells was significantly less compared to control cells from 36h to 72h 
(p<0.05 and 0.01 respectively, Figure 4B).  By contrast, oxygen deprivation caused a similar fall in 
TEER in control and CB1Kd cells after 4h, 6h or 8h of hypoxia (Figure 4C). In both CB1Kd and 
control cells, a recovery in TEER occurred after 4h of hypoxia, though not after 6 or 8h periods. 
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Effects of hypoxia and inflammation on the endogenous production of AEA and 2-AG 
Because inflammatory conditions and hypoxia caused a fall in TEER similar to the effect of FAAH 
and MAGL inhibition in non-inflamed Caco-2 cells, we sought to find the effect of hypoxia and 
inflammation on the endogenous production of AEA and 2-AG. Neither hypoxia nor inflammatory 
cytokines had any significant effect on the production of endogenous AEA (Figure 5A), however 
both conditions caused a significant increase in the production of 2-AG (p<0.0001, Figure 5 B). 
Effects of AEA and 2-AG on the production of inflammatory cytokines 
As inflammation, hypoxia, application of AEA or 2-AG, or inhibition of their degradation, caused 
a fall in TEER in Caco-2 monolayers, we sought to find if AEA or 2-AG have any pro-
inflammatory effects after 24 hours of exposure.  Externally applied AEA, URB597 and JZL184 
caused a decrease in the production of IL-8 compared to vehicle (figure 5C), and AEA, 2-AG, 
URB597 and JZL184 all caused reduced levels of IL-6 (figure 5D), confirming their previously 
establish anti-inflammatory effects. 
Effect of URB597 and JZL184 on the production of inflammatory cytokines in human 
colonic tissue 
We then sought to find the effect of FAAH and MAGL inhibition on the inflammatory response in 
human colonic tissue, using Multiplex analysis to measure a range of cytokines.  Inflammation 
caused a significant rise in the secretion of GM-CSF, IL13 and IL-15 (all p<0.05, fig 6 A, C & D) 
and IL-12 (p<0.01, fig 6 B), and a non-significant increase in the secretion of IL-1β and MIP-1α 
(fig 6 E & F).  IFNγ and TNFα did not affect the secretion of IL-10 and MCP-1 (data not shown). 
Both URB957 and JZL184 significantly prevented an increase in secretion of GM-CSF, IL-12, IL-
13 and IL-15 in the presence of inflammation.  URB597 and JZL184 also prevented the non-
significant increase in the secretion of IL-1βα and MIP-1α.    URB597 and JZL184 alone had no 
effect on any of the measured cytokine levels. The anti-inflammatory effects of URB597 and 
JZL184 were prevented by the AM251, but not SB366791 (fig 6).   Alone, the CB1 and TRPV1 
antagonists did not affect cytokine secretion. 
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Discussion 
We have previously shown that exogenously applied endocannabinoids increase the permeability 
of the intestinal epithelium  (16, 17). In the present study, we sought to investigate the effects of the 
endogenously produced endocannabinoids AEA and 2-AG, by inhibiting their degradation, on 
intestinal permeability under control, inflammatory and hypoxic conditions, and explore the role of 
CB1 in modulating gut permeability. Our data show that FAAH and MAGL cause an increase in 
epithelial permeability through activation of CB1 at the apical surface in control conditions, or when 
permeability is increased by inflammation or hypoxia, whilst simultaneously reducing 
inflammatory cytokine levels in Caco-2 cells.  Knockdown of the CB1 receptor reduced the 
permeability response to inflammation. In contrast, blocking endocannabinoid degradation under 
hypoxic conditions reduced the recovery of epithelial resistance. We also found that 2-AG is 
produced by intestinal epithelial cells in response to inflammation and hypoxia, but not AEA.  
Finally, we compared the anti-inflammatory effects of FAAH and MAGL inhibition seen in Caco-
2 cells to their effect on the inflammatory response in human tissue.  We found that FAAH and 
MAGL inhibition in explant human colonic tissue were anti-inflammatory, and that CB1 blockade 
prevented their effects.  We suggest that endogenous production of endocannabinoids by intestinal 
epithelial cells increases permeability and simultaneously prevents inflammation through CB1.   
We previously reported that apical application of exogenous AEA and 2-AG increased permeability 
in Caco-2 monolayers and sought to examine in the present study whether upregulation of cellular 
endocannabinoids by inhibition of their degradation would have a similar effect. In agreement with 
our previous study we found that inhibition of FAAH and MAGL at the apical membrane causes 
increased permeability and this effect was inhibited by CB1 receptor antagonism or knockdown, 
confirming the role for CB1 in modulating gut permeability. As URB597 and JZL184 do not activate 
CB1  (32, 33), this suggests that accumulation of endogenously produced AEA and 2-AG at the 
apical epithelial layer increase permeability via CB1  (16).   
Treatment of Caco-2 cells with inflammatory cytokines caused nearly a 20% drop in TEER 
(increased permeability). Apical treatment with both URB597 or JZL184 caused a further decrease 
in TEER in addition to the effect of the cytokines, in line with our previous studies in which falls in 
TEER caused by inflammation were exacerbated by the apical application of AEA and 2-AG   (17). 
Furthermore, hypoxia caused ~35% drop in TEER, with recovery and return to baseline 
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permeability over 72 hours. As in the inflammatory protocol, treatment with URB597 and JZL184 
delayed the recovery of TEER compared to control cells. We therefore hypothesise that 
endocannabinoids, via CB1, play a key role in the development and recovery from permeability 
increases caused by inflammation. To investigate this hypothesis, we conducted similar 
permeability experiments with CB1Kd cells and found that CB1Kd monolayers exposed to 
inflammatory cytokines do not exhibit as great a decrease in permeability compared to control cells. 
However, no differences were seen between control and CB1Kd cells subjected to hypoxic 
conditions. This suggests that in the gut, CB1 is a critical component of the permeability changes 
seen in inflammation but not hypoxia.  
Interestingly we have found that basolateral FAAH inhibition increased permeability and this was 
inhibited by antagonism of both CB1 and TRPV1. However, in the presence of CB1 knockdown, 
FAAH inhibition had no effect on permeability, i.e. no contribution of TRPV1 remained after CB1 
knockdown.  This suggests that at the basolateral layer the ability for TRPV1 to modulate 
permeability is dependent on the presence and activation of CB1.  This may be because AEA 
agonism of CB1 causes positive allosteric modulation of the TRPV1 receptor. Alternatively, 
stimulation of CB1 may cause accumulation of a second ligand, which may occupy or positively 
modulate TRPV1.  Supporting this, it has been shown that CB1 activation increases the secretion of 
palmitoylethanolamide (PEA), which then may cause a conformational change in the TRPV1 
receptor, greatly increasing its affinity for AEA  (34, 35). This “entourage effect” has been seen in 
the endocannabinoid system, though has not yet been fully defined  (34, 36).   
Another finding within this study is that JZL184 caused increased permeability at the apical layer, 
but decreased permeability at the basolateral layer. Both effects were prevented by CB1 antagonism 
with AM251. We also confirmed that exogenous application of 2-AG (but not AEA) decreased 
permeability at the basolateral membrane.  Not only is it interesting that 2-AG has differential 
effects on permeability at each membrane, but also that activation of the same basolateral CB1 
receptors with AEA caused an increase in permeability, the opposite effect. The latter observation 
may be explained by structural differences between AEA and 2-AG at the CB1 binding site, as it 
has previously been observed that 2-AG can produce greater differences in intracellular [Ca2+]  (37–
39). It is conceivable therefore, that differential permeability effects at the same receptor sites are 
due receptor bias at CB1, in addition to the effects of TRPV1 co-dependency described above. What 
15 
 
is yet to be determined is the physiological mechanism that causes opposing permeability effects at 
different sides of the epithelium with the same ligand.   
Hypoxia and inflammation in this study both caused an increase in the production of intracellular 
or secreted 2-AG. This supports previous suggestions that increased of endocannabinoids in human 
intestinal tissue acting at CB1 can lead to alterations in gastrointestinal permeability and have an 
anti-inflammatory in response to an inflammatory stimulus  (40).  For example in samples from 
patients with Ulcerative Colitis, Crohn’s disease and Coeliac disease, all diseases of inflammation 
and increased permeability, levels of AEA or 2-AG have been found to be raised  (26, 41, 42). 
Furthermore, inflammatory bowel disease patients with the highest disease scores were found to 
have the highest gut AEA concentrations  (43).  This suggests that there may be an association 
between high levels of AEA and 2-AG, acting at the CB1 receptor in response to an inflammatory 
stimulus, leading to increased gut permeability and its secondary consequences such as 
translocation of bacterial and lipopolysaccharide, but also simultaneously decreasing the 
inflammatory response.   
We found that AEA and 2-AG, or inhibition of their catabolism, exert an anti-inflammatory effect 
on Caco-2 epithelial cells manifesting as a reduction in IL-6 and IL-8 secretion. To support these 
findings we repeated parallel experiments in explant human colonic tissue and found for the first 
time that inhibition of FAAH and MAGL had significant anti-inflammatory effects. We found these 
effects were blocked by antagonism of the CB1 receptor.  Coupled with our permeability findings 
in the Caco-2 cells, we hypothesise that the permeability-enhancing effects of AEA and 2-AG are 
therefore likely to be distinct from their anti-inflammatory role.  In support of the anti-inflammatory 
effect of CB1 agonism, CB1 deficient mice are more susceptible to experimental colitis  (44) and 
administration of AEA or FAAH to mice with TNBS-induced colitis decreases the inflammatory 
response  (23, 27). Additionally, studies in explant human tissue treated with pro-inflammatory 
cytokines have shown that AEA appears to prevent inflammation of the epithelium measured by 
macro and microscopic colitis scores, and levels of matrix metalloproteinase activity  (45, 46).  The 
effect of 2-AG in human colonic tissue has not yet been reported.  This is the first study to report 
the anti-inflammatory effect of endogenously enhanced AEA and 2-AG concentrations in human 
colonic tissue.  AEA and 2-AG therefore are likely to have dual roles as anti-inflammatory and pro-
permeability agents. As the CB1 receptor may be a target for treating diseases such as Ulcerative 
Colitis and Crohn’s disease further work must focus on how these two agents cause their effects 
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downstream from receptor activation.  Additionally we investigated for a role for TRPV1, as seen 
in basolateral Caco-2 cells, but found that its blockade did not affect the inflammatory response. 
In conclusion we have shown in a Caco-2 model of intestinal permeability that endogenous 
production of AEA and 2-AG increases the permeability of epithelial monolayers, both in health 
and disease states, despite simultaneously producing anti-inflammatory effects both in cell culture 
and explant human tissue.  However, our data also showed that 2-AG has opposite effects on 
permeability at the apical and basolateral membranes, and that AEA and 2-AG activation of CB1 
receptors at the basolateral membrane have opposite effects on permeability. 2-AG is upregulated 
by inflammation and hypoxia in this model. This complex pharmacology suggests further studies 
are required to fully understand the role of the endocannabinoid system in modulating gut 
permeability, and that pharmacological manipulation may lead to effective new therapeutic 
approaches to serious intestinal diseases. 
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Figure Legends 
Figure 1.  Increasing anandamide concentrations (using URB597) increases Caco-2 
permeability via CB1.   
The effects of URB597 applied apically (A) or basolaterally (C). Integrated response over time 
(area under curve) on the effects of URB597 in the presence of various receptor antagonists (B 
and D), on Caco-2 permeability as measured by TEER.  Data are given as means and standard 
error bars S.E.M (n=3).  Concentration response curves were compared by two-way repeated 
measures ANOVA with Dunnett's post-hoc test comparing against the vehicle response (*). 
Integrated response over time (AUC) data were compared using one-way ANOVA with post hoc 
analysis of selected pairs (* verses vehicle, † verses URB597 3µM alone; * p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001, ††††<0.0001). 
Figure 2. Increasing 2-AG concentrations (using JZL184) modulates Caco-2 permeability via 
CB1.  
The effects of JZL184 applied apically (A) and basolaterally (C) on Caco-2 permeability as 
measured by TEER. Integrated response over time (area under curve) on the effects of receptors 
antagonists on JZL184 apically (B) and basolaterally (D). The effects of basolateral application of 
AEA and 2-AG on Caco-2 permeability (E). Data are given as means and standard error bars S.E.M. 
(n=3). Concentration-response curves were compared by two-way repeated measures ANOVA with 
Dunnett’s post-hoc test comparing against the vehicle response (*). Integrated response over time 
(AUC) data were compared using one-way ANOVA with post hoc analysis of selected pairs (* 
denotes verses vehicle; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
Figure 3. Increasing AEA or 2-AG causes further increases in permeability after inflammation 
or hypoxia.  
A. The effect of URB597 and JZL184 applied after 24 hours inflammatory cytokine treatment on 
Caco-2 permeability as measured by TEER. B. The effect of URB597 and JZL184 after 4 hours of 
hypoxia on Caco-2 permeability as measured by TEER (B). Data are given as means with error bars 
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representing SEM (n=3,* P<0.05, ** P< 0.01 *** P<0.001), comparing between control and 
experimental data by two-way ANOVA with Dunnett's post-hoc test. 
Figure 4. CB1 contributes to increased permeability associated with inflammation but not 
hypoxia.   
The effect of URB597 and JZL184 (apical and basolateral) in Caco-2 CB1kd cells on permeability 
as measured by TEER (A). The effect of pro-inflammatory cytokines (B) and hypoxia (C) in wild 
type and CB1KO Caco-2 cells on permeability as measured by TEER.  Data are given as means 
with error bars representing SEM (* p<0.05, ** p<0.01 *** p<0.001 compared to control, # 
p<0.05, ## p<0.01 ## compared to wild type Caco-2 cells). Data were compared by ANOVA with 
Dunnett's post-hoc test. 
Figure 5.  2-AG is increased by hypoxia and inflammation, and both AEA and 2-AG are 
anti-inflammatory in Caco-2 cells.  
The effects of hypoxia and inflammation on the endogenous production of AEA (A) and 2-AG 
(B) in cultured Caco-2 cells determined by LC-MS. The effects of AEA and 2-AG on cytokine 
production in Caco-2 cells determined by ELISA (C and D respectively).  Data are given as means 
and standard error bars S.E.M, (n=6, * P<0.05, ** P< 0.01 *** P<0.001), comparing control and 
experimental data by one-way ANOVA with Dunnett's post-hoc test. 
Figure 6: URB597 and JZL184 are anti-inflammatory in the human colon, acting via CB1  
The effects of URB597 and JZL184 on the secretion of GM-CSF (A), IL-12 (B), IL-13 (C) IL-15 
(D), MIP-1a (E) & IL-1b (F) in response to an inflammatory protocol in explant human colonic 
tissue in the presence of antagonists of CB1 (AM251) and TRPV1 (SB366791),  measured by 
multiplex (compared using repeated measures ANOVA, n=7). Data presented as mean +/- SEM 
per condition. * represent significant difference from vehicle, *<0.05, **<0.01, ***<0.001. 
